Our Pricing

Wegovy (Semaglutide) Weight Loss Treatment — UK Stock Availability

Published on: June 03, 2026

When you buy Wegovy in stock UK from Cured Pharmacy, you'll access all doses with transparent pricing from £79.00 genuine UK-licensed pens, and free clinical assessment by our registered prescribers. With ongoing supply challenges affecting many pharmacies, we maintain consistent stock levels across the full dose range to support your weight management journey without interruption.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related health conditions [1]. Semaglutide mimics the action of glucagon-like peptide-1, a natural hormone that regulates appetite and food intake by acting on brain regions responsible for hunger signals.

In the landmark STEP 1 trial involving 1,961 adults, participants using semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. These results represent some of the most substantial weight loss outcomes demonstrated in pharmaceutical trials for obesity management.

The medication works through multiple mechanisms: it slows gastric emptying to prolong feelings of fullness, reduces appetite through central nervous system pathways, and improves glycaemic control. This multi-pathway approach explains why clinical trial participants reported sustained appetite suppression and reduced food cravings throughout treatment [2].

Wegovy Dosing Schedule and All Available Strengths

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic outcomes. The treatment begins with 0.25mg weekly for four weeks, then increases progressively through 0.5mg, 1mg, and 1.7mg doses, reaching the maintenance dose of 2.4mg by week 17 [3].

At Cured Pharmacy, we maintain stock of all five Wegovy dose strengths: 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg pre-filled pens. This complete range ensures uninterrupted treatment progression, which is critical for both tolerability and efficacy. Each pen delivers a single weekly dose, and the gradual titration schedule allows your body to adapt to the medication whilst reducing the likelihood of nausea or other digestive symptoms.

Your UK prescriber will determine your starting dose based on your medical history, current medications, and weight management goals. The assessment considers factors including previous GLP-1 experience, gastrointestinal tolerance, and any contraindications. Most patients follow the standard escalation pathway, though some may require extended time at lower doses if side effects occur.

What Happens If I Miss a Dose?

If you miss your weekly Wegovy injection and fewer than five days have passed since your scheduled dose, administer it as soon as you remember. If more than five days have elapsed, skip the missed dose entirely and resume your regular schedule with the next planned injection [3]. Never double up doses to compensate for a missed injection, as this significantly increases the risk of gastrointestinal side effects.

Wegovy vs Mounjaro: Comparing GLP-1 Weight Loss Treatments

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are injectable medications licensed in the UK for chronic weight management, but they differ in their mechanism of action and clinical outcomes. Wegovy activates GLP-1 receptors exclusively, whilst Mounjaro is the first dual GIP/GLP-1 receptor agonist, targeting two complementary metabolic pathways [4].

Head-to-head trial data from the SURPASS-2 study demonstrated that tirzepatide produced greater weight reduction than semaglutide 1mg in adults with type 2 diabetes, with the highest tirzepatide dose achieving average weight loss of 15.7kg compared to 5.7kg with semaglutide over 40 weeks [4]. However, direct comparisons between Mounjaro and Wegovy's 2.4mg maintenance dose remain limited, and both medications show substantial efficacy in appropriately selected patients.

Your choice between these treatments depends on multiple factors including your medical history, previous medication responses, budget considerations, and prescriber recommendation. Some patients experience better tolerability with one medication over the other, whilst others may achieve their target weight loss with either option when combined with lifestyle modifications.

Can I Switch Between Wegovy and Mounjaro?

Switching between GLP-1 medications is possible under prescriber supervision, though it requires careful dose adjustment and monitoring. If you're considering a change due to side effects, inadequate weight loss, or supply issues, discuss this with your clinician during your consultation. They'll assess whether switching is appropriate and determine the correct starting dose based on your current treatment and response.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Wegovy involve the gastrointestinal system, particularly during dose escalation phases. In clinical trials, nausea affected approximately 44% of participants, whilst vomiting, diarrhoea, and constipation occurred in 24%, 30%, and 24% respectively [1]. These symptoms typically diminish as your body adapts to the medication, with most patients reporting improvement after several weeks at each dose level.

To minimise digestive discomfort, eat smaller, more frequent meals rather than large portions, avoid high-fat and heavily processed foods, and stay well-hydrated throughout the day. Injecting Wegovy at the same time each week and choosing a day when you can rest if needed may help you manage any temporary side effects. If nausea persists or becomes severe, contact your prescriber — they may recommend extending your time at the current dose before escalating further.

Serious adverse events are uncommon but require immediate medical attention. These include signs of pancreatitis (severe abdominal pain radiating to the back), symptoms of thyroid tumours (persistent hoarseness, difficulty swallowing, neck lump), severe allergic reactions, or signs of gallbladder problems. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though relevance to humans remains uncertain [3]. Your prescriber will review your personal and family medical history to ensure Wegovy is appropriate for you.

Who Can Use Wegovy? Eligibility and Contraindications

Wegovy is licensed in the UK for adults with a body mass index of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [3]. NICE guidance recommends considering GLP-1 receptor agonists as part of a specialist weight management service for people who meet these criteria and have not achieved adequate weight loss through lifestyle interventions alone.

The medication is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment. Wegovy is not recommended for people under 18 years or those with severe gastrointestinal disease, including inflammatory bowel disease or diabetic gastroparesis.

During your online consultation at Cured Pharmacy, our UK-registered prescribers will assess your medical history, current medications, and weight management goals to determine whether Wegovy is suitable and safe for you. This assessment typically takes under three minutes to complete and includes questions about previous weight loss attempts, existing health conditions, and any medications that might interact with semaglutide.

Can I Use Wegovy If I Have Type 2 Diabetes?

Yes, Wegovy is licensed for weight management in adults with type 2 diabetes, provided your condition is adequately controlled. However, if you're already taking other GLP-1 medications such as Ozempic for diabetes management, you should not use Wegovy concurrently as this would result in duplicative therapy. Your prescriber will review your current diabetes medications and adjust your treatment plan accordingly to avoid interactions or hypoglycaemia risk.

How to Buy Wegovy In Stock UK from Cured Pharmacy

Ordering Wegovy from Cured Pharmacy begins with our free online consultation, which connects you with a UK-registered prescriber who will review your eligibility. The assessment covers your medical history, current health status, weight management goals, and any medications you're currently taking. Unlike some services that charge consultation fees separately, our clinical assessment is included at no additional cost, with transparent pricing displayed upfront.

Once your prescriber approves your treatment, your medication is dispensed from our GPhC-registered pharmacy (registration number 9012511) under the supervision of our superintendent pharmacist, Tarun Kumar (GPhC 2233073). We dispatch all orders in discreet, unmarked packaging via next-day delivery, ensuring your privacy and convenience. All Wegovy pens supplied are genuine UK-licensed products sourced through authorised pharmaceutical distributors.

We maintain consistent stock levels across all five Wegovy doses, addressing the supply challenges that have affected UK pharmacies throughout 2023 and 2024. Our inventory management system prioritises existing patients to prevent treatment interruptions during dose escalation, whilst welcoming new patients when stock permits. You can verify current availability for your required dose before completing your consultation, and our pharmacy team will contact you directly if any supply issues arise that might affect your order.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and individual results may vary. The efficacy and safety data presented are derived from clinical trials; your personal experience may differ.